Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 8 September 2023, including: the rise of Novo Nordisk A/S; senior level changes at Novartis AG; Moderna, Inc.’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim GmbH’s head of innovation on R&D priorities.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Now Europe’s Most Valuable Company, Can Novo Nordisk Live Up To Investor Expectations?" - Scrip, 6 Sep, 2023.)
(Also see "Novartis Appoints AbbVie Immunology Leader Horber To Succeed Tschudin" - Scrip, 6 Sep, 2023.)
(Also see "Moderna COVID-19 Vaccine First Past The Post With Clinical Data For BA.2.86" - Scrip, 6 Sep, 2023.)
(Also see "Schizophrenia, Depression And Neuropathy: What’s Coming In 2024" - Scrip, 8 Sep, 2023.)
(Also see "Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition" - Scrip, 4 Sep, 2023.)